Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2013Website:
http://www.agios.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 04 Nov 2024 21:02:16 GMTDividend
Analysts recommendations
Institutional Ownership
AGIO Latest News
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2024.
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights.
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the Company will receive a total of $1.1 billion in milestone payments following the U.S. Food and Drug Administration (FDA) approval of vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery, including biopsy, sub-total resection or gross total resection.
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 –
What type of business is Agios Pharmaceuticals?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of drugs in the field of cellular metabolism for patients with hematologic malignancies, oncology tumors, and rare genetic diseases. The company was registered in August 2007. The executive office is located in Cambridge, Massachusetts. The scientific approach of Agios Pharmaceuticals, Inc. is focused on using its proprietary technology to identify key metabolic enzymes in cancer or other diseased cells in the laboratory, and then using these key enzymes for screening and identifying candidate products targeting cellular metabolism and related areas of biology. The company's efforts are also focused on metabolic immuno-oncology.
What sector is Agios Pharmaceuticals in?
Agios Pharmaceuticals is in the Healthcare sector
What industry is Agios Pharmaceuticals in?
Agios Pharmaceuticals is in the Biotechnology industry
What country is Agios Pharmaceuticals from?
Agios Pharmaceuticals is headquartered in United States
When did Agios Pharmaceuticals go public?
Agios Pharmaceuticals initial public offering (IPO) was on 24 July 2013
What is Agios Pharmaceuticals website?
https://www.agios.com
Is Agios Pharmaceuticals in the S&P 500?
No, Agios Pharmaceuticals is not included in the S&P 500 index
Is Agios Pharmaceuticals in the NASDAQ 100?
No, Agios Pharmaceuticals is not included in the NASDAQ 100 index
Is Agios Pharmaceuticals in the Dow Jones?
No, Agios Pharmaceuticals is not included in the Dow Jones index
When was Agios Pharmaceuticals the previous earnings report?
No data
When does Agios Pharmaceuticals earnings report?
Next earnings report date is not announced yet